Edition:
United Kingdom

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

0.00SEK
14 Dec 2018
Change (% chg)

-37.50kr (-100.00%)
Prev Close
37.50kr
Open
--
Day's High
--
Day's Low
--
Volume
0
Avg. Vol
1,340,607
52-wk High
39.40kr
52-wk Low
25.25kr

Latest Key Developments (Source: Significant Developments)

EQT makes 6 bln SEK bid for specialty pharma firm Karo Pharma
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Karo Pharma AB ::EQT VIII, THROUGH KARO INTRESSENTER AB, ANNOUNCES A PUBLIC CASH OFFER TO THE SHAREHOLDERS IN KARO PHARMA AKTIEBOLAG.EQT SAYS PUBLIC CASH OFFER TO SHAREHOLDERS IN KARO PHARMA AKTIEBOLAG TO ACQUIRE SHARES IN KARO PHARMA AT A PRICE OF SEK 36.90 PER SHARE.EQT SAYS TOTAL OFFER VALUE BASED ON ALL OUTSTANDING SHARESIN KARO PHARMA AMOUNTS TO SEK 5,973 MILLION.EQT SAYS OFFER IS FULLY FINANCED THROUGH EQUITY FROM EQT VIII.EQT SAYS OFFER REPRESENTS A PREMIUM OF 25.3 PER CENT FOR SHARES IN RELATION TO CLOSING PRICE FOR SHARES ON NASDAQ STOCKHOLM ON 26 OCTOBER 2018.EQT SAYS BOARD OF DIRECTORS OF KARO PHARMA HAS UNANIMOUSLY RECOMMENDED THAT COMPANY'S SHAREHOLDERS ACCEPT OFFER.EQTSAYS ANDERS LONNER, CHAIRMAN OF COMPANY'S BOARD OF DIRECTORS, AND PER-ANDERS JOHANSSON, MEMBER OF COMPANY'S BOARD OF DIRECTORS, TOGETHER REPRESENTING IN ABT 13.6 PERCENT OF OUTSTANDING VOTES IN COMPANY, HAVE DECLARED THAT THEY INTEND TO ACCEPT OFFER.  Full Article

Karo Pharma Triples Sales And Profit In The Second Quarter
Thursday, 19 Jul 2018 

Karo Pharma AB ::KARO PHARMA TRIPLES SALES AND PROFIT IN THE SECOND QUARTER.EBITDA Q2 AMOUNTED TO MSEK 232.3 (49.7).Q2 NET SALES MSEK 489.4 (142.5).QUARTER WAS POSITIVELY IMPACTED BY FACT THAT AC-QUIRED PRODUCTS FROM LEO WERE INCLUDED FOR FIRST TIME..KARO PHARMA - "EXPECTED FUTURE PROFITS IMPLIES THAT WE CAN NOW UTILIZE OUR TAX LOSSES FOR A NUMBER OF YEARS TO COME, WHICH WILL HAVE A MAJOR POSITIVE IMPACT ON OUR CASH FLOW".  Full Article

Karo Pharma To Acquire Own Shares
Wednesday, 9 May 2018 

May 9 (Reuters) - KARO PHARMA AB ::HAS DECIDED TO ACQUIRE OWN SHARES.A MAXIMUM OF 10,000,000 SHARES SHALL BE ACQUIRED.  Full Article

Karo Pharma Determines Terms For Rights Issue
Monday, 30 Apr 2018 

April 30 (Reuters) - Karo Pharma AB ::THE TERMS FOR KARO PHARMA'S RIGHTS ISSUE HAVE BEEN DETERMINED.FOR EACH EXISTING SHARE HELD AT RECORD DATE, SHAREHOLDERS WILL RECEIVE ONE (1) SUBSCRIPTION RIGHT.SUBSCRIPTION PRICE HAS BEEN SET AT SEK 24.00 PER SHARE.RIGHTS ISSUE WILL AT MOST RAISE SEK 1,314.7 MILLION BEFORE ISSUE COSTS.ISSUANCE OF A MAXIMUM OF 54,777,594 NEW ORDINARY SHARES.TWO (2) SUBSCRIPTION RIGHTS ENTITLING HOLDER TO SUBSCRIBE FOR ONE (1) ORDINARY NEW SHARE (I.E. A SUBSCRIPTION RATIO OF 1:2).SUBSCRIPTION PERIOD WILL RUN BETWEEN 14 MAY 2018 UNTIL 29 MAY 2018.  Full Article

Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue
Wednesday, 4 Apr 2018 

April 4 (Reuters) - KARO PHARMA AB ::THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING.IS EXPECTED TO RECEIVE ISSUE PROCEEDS AMOUNTING TO ABOUT SEK 1.3 BILLION BEFORE TRANSACTION COSTS.  Full Article

Karo Pharma Rights Issue Subscribed To 170 Percent
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - KARO PHARMA AB ::RIGHTS ISSUE SUBSCRIBED TO 170 PERCENT WITH PROCEEDS AT ABOUT SEK 794.3 MILLION BEFORE ISSUE COSTS.  Full Article

Karo Pharma: New Issue To Provide Up To SEK 794.3 Ml‍n Before Issue Costs
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Karo Pharma Ab ::SAYS NEW ISSUE TO PROVIDE UP TO SEK 794.3 ML‍N BEFORE ISSUE COSTS.  Full Article

Karo Pharma Chairman Called For Inquiry For Inside Trading
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Karo Pharma Ab ::CHAIRMAN CALLED IN TO INQUIRY FROM POLICE FOR INSIDE TRADING.BOARD CONCLUDES THE THAT CHAIRMAN HAS ACTED CORRECTLY AND DID NOTHING WRONG, AS PER ITS INVESTIGATION.  Full Article

Karo Pharma signs agreement with Marinomed Biotech
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Karo Pharma Ab ::KARO PHARMA ANNOUNCES AGREEMENT WITH THE AUSTRIAN PHARMACEUTICAL COMPANY MARINOMED BIOTECH AG.‍WILL MARKET A PATENTED PRODUCT FOR COMMON COLD & FLU SYMPTOMS IN SWEDEN, NORWAY AND FINLAND.​.‍AGREEMENT IS LONG TERM (10 YEARS).​.  Full Article

Karo Pharma to carry out new issue
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - KARO PHARMA AB ::TO CARRY OUT NEW ISSUE WITH PROCEEDS AT ABOUT SEK 800 MILLION BEFORE ISSUE COSTS IF FULLY SUBSCRIBED.  Full Article

Karo Pharma says Chairman Anders Lonner has died

STOCKHOLM, Dec 3 Speciality pharma firm Karo Pharma's Chairman Anders Lonner has died, the company said in a statement on Sunday evening.